TICKERNERD
Menu
LIVNLIVNHealthcare · Medical Devices

LIVN Stock Forecast: LivaNova PLC Price Predictions for 2026-2027

Last close, 14 Aug 2026
$82
+0.02% on the day

The 10 Wall Street analysts covering LivaNova PLC hold a median 12-month price target of $92 — +11.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.5B
Ticker Nerd rank
97 / 100
Median analyst target
$92
Analysts covering
10
Total return, dividends reinvested
1W
+7.9%
1M
+3.9%
YTD
+33.6%
1Y
+51.9%
From 52W high
−3.6%
From 52W low
+65.9%
$50
$85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LIVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LivaNova PLC on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
93
Revisions
86
Issuance
85
Growth
84
Quality
80
Volatility
66
Accruals
38
Size
25

Momentum (97): The shares have been drifting up relative to others.

Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LIVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LIVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100Oct 25Jan 26Apr 26Jul 26LIVNHigh $100Median $92Low $75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $75Median $92High $100

The green dot is the last close — the median target sits +11.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026NeedhamMaintainsBuy$81 → $93
15 July 2026MizuhoMaintainsOutperform$90 → $95
15 July 2026MizuhoMaintainsOutperform—
1 July 2026Freedom Capital MarketsInitiatesHold—
22 June 2026KeybancMaintainsOverweight—
7 May 2026BairdMaintainsOutperform—
7 May 2026BarclaysMaintainsEqual-Weight—
7 May 2026MizuhoMaintainsOutperform—
27 Feb 2026BarclaysMaintainsEqual-Weight—
25 Feb 2026NeedhamMaintainsBuy—
9 Jan 2026BarclaysMaintainsEqual-Weight—
7 Jan 2026StifelMaintainsBuy—
19 Dec 2025KeybancInitiatesOverweight—
17 Dec 2025MizuhoMaintainsOutperform—
13 Nov 2025BairdMaintainsOutperform—
13 Nov 2025MizuhoMaintainsOutperform—
6 Nov 2025BairdMaintainsOutperform—
3 Sept 2025NeedhamReiteratesBuy—
21 Aug 2025BarclaysMaintainsEqual-Weight—
20 May 2025Wolfe ResearchUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LIVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LIVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.3%
Analysts raising
0
Analysts cutting
1
Fundamentals

LivaNova PLC (LIVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.3×

Cheaper than 33% of US stocks

Price / sales
3.1×

Cheaper than 41% of US stocks

Price / book
3.4×

Cheaper than 31% of US stocks

EV / EBITDA
16.3×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
10.8%

Higher than 55% of US stocks

Earnings growth (YoY)
299.7%

Higher than 93% of US stocks

Gross margin
70.1%

Higher than 83% of US stocks

Operating margin
15.5%

Higher than 73% of US stocks

Net margin
12.8%

Higher than 75% of US stocks

Returns & dividend
Return on equity
15.4%

Higher than 75% of US stocks

Return on assets
5.2%

Higher than 78% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LIVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LIVNLivaNova PLC$4.5B
97
ITGRInteger Holdings Corp.$4.4B
71
HAEHaemonetics Corp.$4.3B
99
IRTCiRhythm Holdings, Inc.$4.1B
78
TMDXTransMedics Group, Inc.$3.1B
29
AXGNAxoGen, Inc.$2.6B
78
NEOGNeogen Corp.$2.5B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LivaNova PLC — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LIVN news & analysis

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

Zacks Investment Research · 6 Aug 2026positive

LivaNova reported second-quarter earnings and revenues that beat estimates, supported by growth in its Cardiopulmonary and Epilepsy segments. This performance contributed to margin gains and led the company to raise its 2026 outlook.

Why it matters — A LivaNova watcher would care because better-than-expected second-quarter results, growth across Cardiopulmonary and Epilepsy, and a raised 2026 outlook point to continued strength in the company's core businesses.

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026positive

LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript

Why it matters — A LIVN watcher would care because it is a source of direct, accurate information about the company's second-quarter 2026 results, which may be useful for assessing the stock.

LivaNova Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

LivaNova reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation, and IT infrastructure.

Why it matters — A LivaNova watcher would care because record results and a raised full-year outlook signal continued momentum, while the reduced free-cash-flow forecast reflects deliberate investment in capacity and infrastructure.

LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 5 Aug 2026neutral

LivaNova reported its second-quarter 2026 earnings. The report examines how key metrics from the quarter compare with Wall Street estimates and year-ago figures.

Why it matters — A LIVN watcher would care because the item shows how the company's quarterly performance stacked up against analyst expectations and the same period last year.

LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?

Zacks Investment Research · 5 Aug 2026positive

LivaNova's stock reached a 52-week high. Zacks Investment Research examined the company's fundamentals to assess whether investors could expect further gains.

Why it matters — The milestone at a 52-week high, along with a review of the company's fundamentals, offers LIVN watchers insight into whether the stock's momentum can be sustained.

FAQ

Frequently asked questions about LIVN stock

What is the LIVN stock price forecast for 2026-2027?

The 10 Wall Street analysts covering LivaNova PLC have a median 12-month price target of $92, with estimates ranging from $75 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LIVN stock a buy right now?

Of the 10 analysts covering LivaNova PLC, 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LivaNova PLC 97 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LIVN?

As at 15 Aug 2026, LivaNova PLC ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will LIVN stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +11.3% from the last close, and Ticker Nerd's factor model ranks LivaNova PLC 97 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LIVN stock forecast for 2030?

No analyst covering LivaNova PLC publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $100 over the next 12 months.

How has LIVN stock performed over the past year?

LivaNova PLC returned +51.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LivaNova PLC do?

LivaNova is a global medical technology company that develops innovative devices and therapies for cardiac surgery, cardiopulmonary support, and neuromodulation treatments. The company's primary product portfolio includes vagus nerve stimulation therapy for drug-resistant epilepsy and difficult-to-treat depression, along with advanced cardiopulmonary solutions for cardiac surgical procedures.

What is the latest news on LIVN?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised". LivaNova reported second-quarter earnings and revenues that beat estimates, supported by growth in its Cardiopulmonary and Epilepsy segments. This performance contributed to margin gains and led the company to raise its 2026 outlook.

Company

About LivaNova PLC.

LivaNova is a global medical technology company that develops innovative devices and therapies for cardiac surgery, cardiopulmonary support, and neuromodulation treatments. The company's primary product portfolio includes vagus nerve stimulation therapy for drug-resistant epilepsy and difficult-to-treat depression, along with advanced cardiopulmonary solutions for cardiac surgical procedures. LivaNova serves healthcare providers and patients worldwide, addressing critical medical needs in neurology and cardiovascular care. Established through the 2015 merger of Cyberonics and Sorin, the company combines decades of expertise in both neuromodulation and cardiopulmonary innovation. Operating through specialized business units headquartered in different regions, LivaNova also maintains a digital health initiative focused on epilepsy treatment support. The company is headquartered in London and employs thousands of professionals dedicated to transforming patient outcomes through advanced medical technology solutions.

CEO Mr. Vladimir A. Makatsaria · 3,300 employees · United Kingdom · https://www.livanova.com